Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T c...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

ThatNurseDude Nov. 15 at 1:59 AM

$PDSB I'm deciding to remain positive. I've talked trash about Frank and am also frustrated, bt I think Frank can still pull this off. That small offering gives me some confidence that Frank is just trying to bridge finance until FDA expedited approval pathway then partnership because no way they can go it alone... Let's get this bag and keep supporting Frank and team and hope this treatment can get to patients! -Holder since 2020...

0 · Reply

dvice2 Nov. 14 at 11:43 PM

$PDSB lookin forward to the r/s and further move down. thats reality here

1 · Reply

Mr_Charlie Nov. 14 at 6:20 PM

$PDSB nothing to see here until FDA decides if they approve quick drug approval process or not. We will go to 1.50$ or 0.20$ depending on this decision. A no will mean bankruptcy for sure.

1 · Reply

Baltic_Roots Nov. 14 at 5:20 PM

$PDSB in 5k shares for now. Profit will go here from rest of investments

1 · Reply

Bilosellhigher Nov. 14 at 3:03 PM

$PDSB The sensitivity analysis of the 9 patients lost to follow-up in V-002 discussed on call yesterday was the the most important topic discussed (IMO). They stated that analysis included accessing the survival records and disease progression status of the 9 patients. Their statistical experts made a censoring analysis and they indicated these patients had no impact on OS or PFS. For the past year I have been calculating OS curves from V-002 data making different assumptions re the outcome of these patients. I convinced myself that even with fairly pessimistic assumptions re outcomes the OS was still superior to SOC. My biggest concern re the trial data is the lack of a control and comparison to studies that include primarily p16- patients that are generally considered to have worse outcomes than p16+ patients.

1 · Reply

EddieH2020 Nov. 14 at 1:52 PM

$PDSB Wainwright is a trash company. Come on man….

0 · Reply

KG1816 Nov. 14 at 12:20 AM

$PDSB lmao. This drisk guy should flag 72% of companies.

2 · Reply

Ontherag Nov. 14 at 12:13 AM

$PDSB 15 by wainwright, interesting

1 · Reply

Marcino11 Nov. 13 at 10:20 PM

$PDSB Hopefully this will help https://www.fiercebiotech.com/biotech/fdas-new-plausible-mechanism-pathway-accelerate-bespoke-gene-editing-therapies

0 · Reply

d_risk Nov. 13 at 9:31 PM

$PDSB - PDS Biotechnology Corporation Common Stock - 10Q - Updated Risk Factors PDSB flags urgent going concern risk tied to April 2025 financing, ongoing losses, and capital needs; updates on $1M Debenture redemption and U.S. regulatory uncertainty; adds new warning on AI-related security threats. #Biotechnology #AISecurityThreats #RegulatoryRisk #FinancingUncertainty #GoingConcernRisk 🟢 Added 🟠 Removed https://d-risk.ai/PDSB/10-Q/2025-11-13

1 · Reply

PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:30 AM EST - 2 days ago

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Nov 11, 2025, 3:31 PM EST - 3 days ago

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

Nov 10, 2025, 8:30 AM EST - 5 days ago

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Nov 6, 2025, 8:00 AM EST - 9 days ago

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Oct 30, 2025, 8:00 AM EDT - 16 days ago

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 29, 2025, 8:37 AM EDT - 17 days ago

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Sep 18, 2025, 8:45 AM EDT - 2 months ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

Sep 2, 2025, 8:00 AM EDT - 2 months ago

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 8:30 AM EDT - 2 months ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Aug 13, 2025, 10:08 AM EDT - 3 months ago

PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:00 AM EDT - 3 months ago

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Aug 6, 2025, 8:00 AM EDT - 3 months ago

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 4 months ago

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jun 9, 2025, 8:00 AM EDT - 5 months ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 2, 2025, 8:00 AM EDT - 5 months ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 5:26 PM EDT - 6 months ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 20, 2025, 8:00 AM EDT - 6 months ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 14, 2025, 12:57 PM EDT - 6 months ago

PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:30 AM EDT - 6 months ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 9, 2025, 4:05 PM EDT - 6 months ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:00 AM EDT - 6 months ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 7, 2025, 8:00 AM EDT - 6 months ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

Apr 23, 2025, 10:16 AM EDT - 7 months ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 7 months ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 7 months ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 27, 2025, 10:35 AM EDT - 8 months ago

PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:30 AM EDT - 8 months ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 25, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 18, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 13, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 11, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech Leadership to Participate in March Conferences

Mar 7, 2025, 8:45 AM EST - 9 months ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Feb 27, 2025, 8:00 AM EST - 9 months ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 26, 2025, 8:00 AM EST - 9 months ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 24, 2025, 8:00 AM EST - 9 months ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 20, 2025, 8:00 AM EST - 9 months ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Dec 3, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Nov 14, 2024, 11:18 AM EST - 1 year ago

PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Oct 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Sep 23, 2024, 10:39 AM EDT - 1 year ago

PDS Biotechnology: Continuing The Holding Pattern

Sep 9, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Sep 3, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 7, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

Aug 2, 2024, 9:12 AM EDT - 1 year ago

PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)

Aug 1, 2024, 7:45 AM EDT - 1 year ago

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

Jul 31, 2024, 4:01 PM EDT - 1 year ago

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

May 15, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

May 9, 2024, 5:46 PM EDT - 1 year ago

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

ThatNurseDude Nov. 15 at 1:59 AM

0 · Reply

dvice2 Nov. 14 at 11:43 PM

$PDSB lookin forward to the r/s and further move down. thats reality here

1 · Reply

Mr_Charlie Nov. 14 at 6:20 PM

$PDSB nothing to see here until FDA decides if they approve quick drug approval process or not. We will go to 1.50$ or 0.20$ depending on this decision. A no will mean bankruptcy for sure.

1 · Reply

Baltic_Roots Nov. 14 at 5:20 PM

$PDSB in 5k shares for now. Profit will go here from rest of investments

1 · Reply

Bilosellhigher Nov. 14 at 3:03 PM

1 · Reply

EddieH2020 Nov. 14 at 1:52 PM

$PDSB Wainwright is a trash company. Come on man….

0 · Reply

KG1816 Nov. 14 at 12:20 AM

$PDSB lmao. This drisk guy should flag 72% of companies.

2 · Reply

Ontherag Nov. 14 at 12:13 AM

$PDSB 15 by wainwright, interesting

1 · Reply

Marcino11 Nov. 13 at 10:20 PM

$PDSB Hopefully this will help https://www.fiercebiotech.com/biotech/fdas-new-plausible-mechanism-pathway-accelerate-bespoke-gene-editing-therapies

0 · Reply

d_risk Nov. 13 at 9:31 PM

1 · Reply

NotBornYesterday Nov. 13 at 9:25 PM

$PDSB

0 · Reply

Mr_Charlie Nov. 13 at 8:46 PM

$PDSB some just increased the price target to $15, so we still have a change of recovering some money!

0 · Reply

Maladia Nov. 13 at 8:16 PM

$PDSB 2k added, too cheap to pass

0 · Reply

The__Shane Nov. 13 at 6:46 PM

$PDSB Over the last year, insiders have collectively bought or received $13.8M worth of shares and sold $0 across 100 transactions. However, focusing on high-impact open-market transactions, insiders purchased $192.2K and sold $0 worth of PDS Biotechnology.

0 · Reply

Test2025 Nov. 13 at 6:29 PM

$PDSB going below 0.5 soon and stay there for a year

0 · Reply

JarvisFlow Nov. 13 at 6:21 PM

HC Wainwright & Co. has updated their rating for PDS Biotechnology ( $PDSB ) to Buy with a price target of 15.

1 · Reply

Ydelaporte Nov. 13 at 5:29 PM

$PDSB really…no-one?

0 · Reply

Ydelaporte Nov. 13 at 3:06 PM

$PDSB ai… happy I sold in time!?

0 · Reply

dvice2 Nov. 13 at 1:42 PM

$PDSB Didnt bother listening to the call..im assuming nothing noteworthy ?

2 · Reply

dvice2 Nov. 13 at 12:52 PM

$PDSB Co needs to provide anticipated timeline of FDA decision and provide information on number patients enrolled/actively receiving treatment to date in ph3.. cash burn was $8 million last quarter..why raise $5 million? minimal dilution in hopes the SP will be greater when next raise comes around? who knows

2 · Reply

rwol9999 Nov. 13 at 12:43 PM

$PDSB so they beat again!!!!

0 · Reply

Ontherag Nov. 13 at 12:43 PM

$PDSB https://www.stocktitan.net/news/PDSB/pds-biotech-reports-third-quarter-2025-financial-results-and-6jbxusn0ktxo.html

0 · Reply

Market Cap	39.74M
Revenue (ttm)	0.00
Net Income (ttm)	-37.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.81

Volume	475,100
Avg Vol	810,510
Day's Range	N/A - N/A
Shares Out	47.03M
Stochastic %K	0%
Beta	1.06
Analysts	Strong Sell
Price Target	$7.50